http://purl.org/np/RA008X0dUg... RA008X0dUg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-27T18:42:27.644Z

http://purl.org/np/RA008X0dUg... RA008X0dUg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

fluocinolone acetonide topical oil is a corticosteroid indicated for the topical treatment of atopic dermatitis in adult patients 1 1 topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks 1 2 limitations of use apply the least amount to cover affected areas discontinue when disease is controlled 1 3 do not use in the diaper area 1 3 do not use on the face axillae or groin 1 3 6 2 8 4 fluocinolone acetonide topical oil is indicated for the topical treatment of atopic dermatitis in adult patients fluocinolone acetonide topical oil is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks safety and effectiveness in pediatric patients younger than 3 months of age have not been established apply the least amount of fluocinolone acetonide topical oil needed to cover the affected areas as with other corticosteroids fluocinolone acetonide topical oil should be discontinued when control of disease is achieved contact the physician if no improvement is seen within 2 weeks fluocinolone acetonide topical oil should not be applied to the diaper area diapers or plastic pants may constitute occlusive use fluocinolone acetonide topical oil should not be used on the face axillae or groin unless directed by the physician application to intertriginous areas should be avoided due to the increased risk of local adverse reactions see adverse reactions 6 use in specific populations 8 4

Leoni Bücken

2021-06-27T18:42:27.644Z

http://purl.org/np/RA008X0dUg... RA008X0dUg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_3310 DOID_3310

Leoni Bücken

2021-06-27T18:42:27.644Z

http://purl.org/np/RA008X0dUg... RA008X0dUg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-27T18:42:27.644Z

http://purl.org/np/RA008X0dUg... RA008X0dUg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00591 drugbank:DB00591

Leoni Bücken

2021-06-27T18:42:27.644Z

http://purl.org/np/RA008X0dUg... RA008X0dUg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-27T18:42:27.644Z

http://purl.org/np/RA008X0dUg... RA008X0dUg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-27T18:42:27.644Z

http://purl.org/np/RA008X0dUg... RA008X0dUg

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-27T18:42:27.644Z